Home › Phases › Phase 3

Phase 3 (69 companies)

Companies with at least one active program at Phase 3.

Ticker	Company	Therapeutic areas	Phase 3 programs	Lead stage	Programs
FDMT	4D Molecular Therapeutics	OphthalmologyRespiratory Rare	1	Phase 3	5
ACIU	AC Immune	Neurology Rare	2	Phase 3	11
ALDX	Aldeyra Therapeutics	DermatologyOncology+1 Rare	2	NDA Submitted	8
ATHE	Alterity Therapeutics	Neurology Rare	1	Phase 3	2
AMLX	Amylyx Pharmaceuticals	MetabolicNeurology Rare	1	Phase 3	5
ANAB	AnaptysBio	DermatologyGI/Hepatology+2 Rare	1	Approved	6
ANNX	Annexon	HematologyNeurology+2 Rare	1	NDA Submitted	6
RCUS	Arcus Biosciences	DermatologyImmunology+1	3	Phase 3	6
ARDX	Ardelyx	Renal	1	Approved	4
ARVN	Arvinas	NeurologyOncology Rare	1	Approved	15
ATAI	Atai Beckley	Neurology	1	Phase 3	5
BCAX	Bicara Therapeutics	Oncology	1	Phase 3	4
BCTX	BriaCell Therapeutics	Oncology	1	Phase 3	8
CRDL	Cardiol Therapeutics	Cardiovascular Rare	1	Phase 3	4
CRBU	Caribou Biosciences	Oncology	1	Phase 3	4
RNAC	Cartesian Therapeutics	ImmunologyNeurology+1 Rare	1	Phase 3	4
CLDX	Celldex Therapeutics	DermatologyImmunology+1	3	Phase 3	7
CRVO	CervoMed	Neurology Rare	1	Phase 3	5
CGEN	Compugen	Oncology	4	Phase 3	7
CRVS	Corvus Pharmaceuticals	DermatologyOncology	1	Phase 3	4
CRNX	Crinetics Pharmaceuticals	MetabolicOncology Rare	1	Approved	6
HELP	Cybin	Neurology	1	Phase 3	3
DFTX	Definium Therapeutics	Neurology	3	Phase 3	4
ENTA	Enanta Pharmaceuticals	DermatologyImmunology+1	1	Phase 3	6
ETON	Eton Pharmaceuticals	GI/HepatologyMetabolic+1 Rare	1	Approved	14
EXEL	Exelixis	CardiovascularOncology	3	Approved	21
EYPT	EyePoint	Ophthalmology	2	Phase 3	3
GUTS	Fractyl Health	Metabolic	1	Phase 3	3
GERN	Geron	Oncology	1	Approved	3
GOSS	Gossamer Bio	Cardiovascular Rare	2	Phase 3	4
GLSI	Greenwich LifeSciences	Oncology	1	Phase 3	1
IMRX	Immuneering	Oncology	1	Phase 3	5
IMUX	Immunic	GI/HepatologyNeurology	1	Phase 3	4
NTLA	Intellia Therapeutics	CardiovascularImmunology Rare	4	NDA Submitted	5
KOD	Kodiak Sciences	Ophthalmology	5	Phase 3	7
KYTX	Kyverna Therapeutics	ImmunologyNeurology+1 Rare	1	NDA Submitted	7
MAIA	MAIA Biotechnology	Oncology	1	Phase 3	7
MDNAF	Medicenna Therapeutics	Oncology	1	Phase 3	9
MIST	Milestone Pharmaceuticals	Cardiovascular	1	Phase 3	3
NGNE	Neurogene	Neurology Rare	1	Phase 3	1
NRXP	NRX Pharmaceuticals	Neurology	1	NDA Submitted	5
OCGN	Ocugen	Infectious DiseaseOphthalmology Rare	4	Phase 3	13
OCS	Oculis Holding	NeurologyOphthalmology	3	Phase 3	5
IRD	Opus Genetics	Ophthalmology Rare	1	Approved	12
OTLK	Outlook Therapeutics	Ophthalmology	2	NDA Submitted	3
TARA	Protara Therapeutics	DermatologyMetabolic+1 Rare	1	Phase 3	3
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	1	Phase 3	10
RYTM	Rhythm Pharmaceuticals	Metabolic Rare	6	Approved	13
SGMT	Sagimet Biosciences	DermatologyMetabolic	2	Phase 3	5
SRPT	Sarepta Therapeutics	Neurology Rare	1	Approved	10
SLS	SELLAS Life Sciences Group	Oncology	1	Phase 3	8
SLDB	Solid Biosciences	CardiovascularNeurology Rare	1	Phase 3	6
SMMT	Summit Therapeutics	Oncology	3	Phase 3	3
TSHA	Taysha Gene Therapies	Neurology Rare	1	Phase 3	4
TENX	Tenax Therapeutics	Cardiovascular Rare	1	Phase 3	2
TGTX	Tg Therapeutics	Neurology Rare	1	Approved	4
TVTX	Travere Therapeutics	MetabolicRenal Rare	1	Approved	7
TTRX	Turn Therapeutics	DermatologyInfectious Disease	1	Phase 3	4
RARE	Ultragenyx Pharmaceutical	CardiovascularGI/Hepatology+2 Rare	4	Approved	12
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	8	Approved	26
VKTX	Viking Therapeutics	GI/HepatologyMetabolic+1 Rare	2	Phase 3	9
VIR	Vir Biotechnology	Infectious DiseaseOncology Rare	1	Phase 3	10
VRDN	Viridian Therapeutics	Ophthalmology	1	Approved	6
VOR	Vor Biopharma	ImmunologyNeurology Rare	2	Phase 3	4
VTVT	vTv Therapeutics	MetabolicRespiratory Rare	1	Phase 3	8
XNCR	Xencor	HematologyImmunology+4 Rare	2	Approved	30
XENE	Xenon Pharmaceuticals	Neurology	3	Phase 3	6
ZBIO	Zenas BioPharma	DermatologyImmunology+1 Rare	2	NDA Submitted	11
ZYME	Zymeworks	OncologyRespiratory	1	Approved	11